natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the
Company profile
Ticker
NTRA
Exchange
Website
CEO
Stephen Chapman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
NTRA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
8-K
Natera Acquires Reproductive Health Assets from Invitae
22 Jan 24
8-K
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
9 Jan 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Natera Reports Third Quarter 2023 Financial Results
8 Nov 23
Transcripts
NTRA
Earnings call transcript
2023 Q4
28 Feb 24
NTRA
Earnings call transcript
2023 Q3
8 Nov 23
NTRA
Earnings call transcript
2023 Q2
3 Aug 23
NTRA
Earnings call transcript
2023 Q1
9 May 23
NTRA
Earnings call transcript
2022 Q4
28 Feb 23
NTRA
Earnings call transcript
2022 Q3
8 Nov 22
NTRA
Earnings call transcript
2022 Q2
6 Aug 22
NTRA
Earnings call transcript
2022 Q1
8 May 22
NTRA
Earnings call transcript
2022 Q4
28 Feb 22
NTRA
Earnings call transcript
2021 Q4
28 Feb 22
Latest ownership filings
144
Notice of proposed sale of securities
24 Apr 24
4
Jonathan Sheena
23 Apr 24
4
DANIEL RABINOWITZ
23 Apr 24
4
Solomon Moshkevich
23 Apr 24
4
John Fesko
23 Apr 24
4
Steven Leonard Chapman
23 Apr 24
4
Michael Burkes Brophy
23 Apr 24
4
Solomon Moshkevich
17 Apr 24
4
Steven Leonard Chapman
17 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 668.71 mm | 668.71 mm | 668.71 mm | 668.71 mm | 668.71 mm | 668.71 mm |
Cash burn (monthly) | (no burn) | (no burn) | 36.99 mm | 41.99 mm | 9.85 mm | 22.50 mm |
Cash used (since last report) | n/a | n/a | 255.25 mm | 289.71 mm | 67.97 mm | 155.22 mm |
Cash remaining | n/a | n/a | 413.46 mm | 379.00 mm | 600.74 mm | 513.49 mm |
Runway (months of cash) | n/a | n/a | 11.2 | 9.0 | 61.0 | 22.8 |
Institutional ownership, Q3 2023
99.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 317 |
Opened positions | 45 |
Closed positions | 42 |
Increased positions | 111 |
Reduced positions | 119 |
13F shares | Current |
---|---|
Total value | 4.91 tn |
Total shares | 120.15 mm |
Total puts | 252.10 k |
Total calls | 132.50 k |
Total put/call ratio | 1.9 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 10.38 mm | $459.48 bn |
Alger Associates | 8.97 mm | $0.00 |
JPM JPMorgan Chase & Co. | 7.56 mm | $334.39 bn |
Fred Alger Management | 6.96 mm | $307.81 bn |
BLK Blackrock | 5.75 mm | $254.60 bn |
Samlyn Capital | 4.40 mm | $194.71 bn |
Millennium Management | 3.43 mm | $151.98 bn |
Sofinnova Investments | 3.10 mm | $137.20 bn |
Alliancebernstein | 3.08 mm | $136.50 bn |
Kynam Capital Management | 3.00 mm | $132.91 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Apr 24 | Solomon Moshkevich | Common Stock | Sell | Dispose S | No | Yes | 91.3792 | 531 | 48.52 k | 117,029 |
23 Apr 24 | John Fesko | Common Stock | Sell | Dispose S | No | Yes | 91.3792 | 522 | 47.70 k | 111,677 |
23 Apr 24 | Daniel Rabinowitz | Common Stock | Sell | Dispose S | No | Yes | 91.3792 | 787 | 71.92 k | 205,552 |
23 Apr 24 | Chapman Steven Leonard | Common Stock | Sell | Dispose S | No | Yes | 91.3792 | 2,552 | 233.20 k | 230,319 |
21 Apr 24 | Sheena Jonathan | Common Stock | Option exercise | Acquire M | No | No | 0 | 143 | 0.00 | 321,364 |
21 Apr 24 | Sheena Jonathan | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 143 | 0.00 | 430 |
21 Apr 24 | Daniel Rabinowitz | Common Stock | Option exercise | Acquire M | No | No | 0 | 644 | 0.00 | 206,339 |
21 Apr 24 | Daniel Rabinowitz | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 644 | 0.00 | 1,932 |
21 Apr 24 | Chapman Steven Leonard | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,775 | 0.00 | 232,871 |
21 Apr 24 | Chapman Steven Leonard | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,775 | 0.00 | 5,324 |
News
Looking Into Natera's Recent Short Interest
23 Apr 24
Goldman Sachs Maintains Buy on Natera, Raises Price Target to $100
15 Apr 24
Natera Announces Publication Of Largest Prospective dd-cfDNA Study In Kidney Transplantation
11 Apr 24
Craig-Hallum Assumes Natera at Buy, Announces Price Target of $117
8 Apr 24
Natera Highlights New Data From 2 Studies Extending Clinical Validation Of Prospera Heart Dd-cfDNA Test For Heart Transplant Recipients
8 Apr 24
Press releases
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
11 Apr 24
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
5 Apr 24
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
14 Mar 24
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
7 Mar 24
Medicare Extends Coverage of Natera's Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
26 Feb 24